Poised For Growth? This Biotech Is Close To Beginning Key Phase 2a Study With Its Lead Candidate

Tiziana Life Sciences TLSA is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis (SPMS), Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Crohn's disease and more.

The company is close to starting an important phase 2a study with its lead product – Intranasal Foralumab – for non-active SPMS and has plans to initiate a separate study for Alzheimer's disease (AD). The FDA recently cleared the investigational new drug (IND) application for the drug.

Learn more here:

Featured photo by National Cancer Institute on  Unsplash

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.